相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice
S. Gahr et al.
BRITISH JOURNAL OF CANCER (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials
Fausto Petrelli et al.
LUNG CANCER (2012)
被撤回的出版物: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib (Retracted article. See vol. 54, pg. 269, 2013)
Minkyu Jung et al.
YONSEI MEDICAL JOURNAL (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors
Myung Hee Chang et al.
CANCER (2011)
Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer
Ming-Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Adenocarcinoma
Kazuo Kasahara et al.
CLINICAL CANCER RESEARCH (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib
Fengsheng Chen et al.
MEDICAL ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Ivette F. Emery et al.
BMC CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Molecular predictive and prognostic markers in non-small-cell lung cancer
Linda E. Coate et al.
LANCET ONCOLOGY (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
K. Tamura et al.
BRITISH JOURNAL OF CANCER (2008)
Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer
Katsuhiro Masago et al.
CANCER SCIENCE (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
Edward S. Kim et al.
LANCET (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Daniel B. Costa et al.
LUNG CANCER (2007)
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer:: The ONCOBELL trial
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alteration of the serum levels of the epidermal growth factor receptor and its ligands in patients with non-small cell lung cancer and head and neck carcinoma
Y. Lemos-Gonzalez et al.
BRITISH JOURNAL OF CANCER (2007)
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer
N. van Zandwijk et al.
ANNALS OF ONCOLOGY (2007)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers
N Ishikawa et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer
T Takano et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer
T Okamoto et al.
EUROPEAN JOURNAL OF CANCER (2005)
Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology
PA Jänne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
JA Engelman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer
V Gregorc et al.
CLINICAL CANCER RESEARCH (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
